CLSD News and Press, Clearside Biomedical Inc. From 05/13/25

2025-05-13 17:35:54 ET More on Clearside Biomedical Clearside Biomedical, Inc. (CLSD) Q4 2024 Earnings Conference Call Transcript Clearside outlines pivotal Phase 3 plans for CLS-AX in wet AMD Clearside Biomedical GAAP EPS of -$0.10 in-line, revenue of $0.3M beats by...

ALPHARETTA, Ga., May 09, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ...

ALPHARETTA, Ga., May 08, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ...

Ironwood Pharmaceuticals Inc. (IRWD) is expected to report $-0.05 for Q1 2025 CaliberCos Inc. (CWD) is expected to report $-0.4 for Q1 2025 BlackRock TCP Capital Corp. (TCPC) is expected to report $0.34 for Q1 2025 INmune Bio Inc. (INMB) is expected to report $-0.43 for Q1 2025 No...

ALPHARETTA, Ga., May 01, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that management will participate in a ...

ALPHARETTA, Ga., April 01, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that George Lasezkay, PharmD, JD, Pr...

2025-03-27 20:31:43 ET More on Clearside Biomedical Clearside Biomedical, Inc. (CLSD) Q4 2024 Earnings Conference Call Transcript Clearside Biomedical GAAP EPS of -$0.10 in-line, revenue of $0.3M beats by $0.01M Seeking Alpha’s Quant Rating on Clearside Biomed...

2025-03-27 20:31:03 ET Clearside Biomedical, Inc. (CLSD) Q4 2024 Earnings Conference Call March 27, 2025, 04:30 PM ET Company Participants Jenny Kobin - IR George Lasezkay - CEO Victor Chong - Chief Medical Officer Charlie Deignan - CFO ...

2025-03-27 16:08:23 ET More on Clearside Biomedical Seeking Alpha’s Quant Rating on Clearside Biomedical Historical earnings data for Clearside Biomedical Financial information for Clearside Biomedical Read the full article on Seeking Alpha For...

- Successful End-of-Phase 2 Meeting with FDA Results in Alignment on Phase 3 Plans for CLS-AX in Wet AMD - - Asia-Pacific Partner’s New Drug Application for ARCATUS ® (XIPERE ® ) for Uveitic Macular Edema Accepted for Regulatory Review in China - -...